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Abstract: Metformin (MET) is currently being used in several trials for cancer prevention or treatment
in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of
total vitamin B12. In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET,
whose participants were characterized by different components of metabolic syndrome, we tested
the effect of MET on serum levels of B12, holo transcobalamin II (holo-TC-II), and methylmalonic
acid (MMA). The study was conducted on 165 women receiving MET or placebo for three years.
Results of the study indicate a significant overall reduction in both serum total B12 and holo-TC-II
levels according with MET-treatment. In particular, in the MET group 26 of 81 patients and 10 of
the 84 placebo-treated subjects had B12 below the normal threshold (<221 pmol/L) at the end of
the study. Considering jointly all B12, Holo-TC-II, and MMA, 13 of the 165 subjects (10 MET and
3 placebo-treated) had at least two deficits in the biochemical parameters at the end of the study,
without reporting clinical signs. Although our results do not affect whether women remain in the
trial, B12 monitoring for MET-treated individuals should be implemented.
Keywords: metformin; vitamin B12; holotranscobalamin II; methylmalonic acid
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1. Introduction
Metformin (MET) is the first-line treatment for type-2 diabetes and has been used for decades to
treat this chronic condition [1]. Given its favorable effects on glycemic control, weight patterns, insulin
requirements, and cardiovascular outcomes, MET has been recently proposed in addition to lifestyle
interventions to reduce metabolic syndrome (MS) and age-related chronic diseases [2]. Observational
studies have also suggested that diabetic patients treated with MET had a significantly lower risk of
developing cancer or lower cancer mortality than those untreated or treated with other drugs [3,4]. For
this reason, a number of clinical trials are in progress in different solid cancers.
One of the limitations in implementing long-term use of MET to prevent chronic conditions in
healthy subjects relates to its potential lowering effect on vitamin B12 (B12). The aim of the present study
was to assess the effect of three years of MET treatment in a randomized, controlled trial considering
both B12 levels and biomarkers of its metabolism and biological effectiveness.
Cobalamin, also known as B12, is a water-soluble, cobalt-containing vitamin. All forms of
B12 are converted intracellularly into adenosyl-Cbl and methylcobalamin—the biologically active
forms at the cellular level [5]. Vitamin B12 is a vital cofactor of two enzymes: methionine synthase
and L-methyl-malonyl-coenzyme. A mutase in intracellular enzymatic reactions related to DNA
synthesis, as well as in amino and fatty acid metabolism. Vitamin B12, under the catalysis of the
enzyme l-methyl-malonyl-CoA mutase, synthesizes succinyl-CoA from methylmalonyl-CoA in the
mitochondria. Deficiency of B12, thus results in elevated methylmalonic acid (MMA) levels.
Dietary B12 is normally bound to proteins. Food-bound B12 is released in the stomach under
the effect of gastric acid and pepsin. The free vitamin is then bound to an R-binder, a glycoprotein
in gastric fluid and saliva that protects B12 from the highly acidic stomach environment. Pancreatic
proteases degrade R-binder in the duodenum and liberate B12; finally, the free vitamin is then bound
by the intrinsic factor (IF)—a glycosylated protein secreted by gastric parietal cells—forming an IF-B12
complex [6]. The IF resists proteolysis and serves as a carrier for B12 to the terminal ileum where
the IF-B12 complex undergoes receptor (cubilin)-mediated endocytosis [7]. The vitamin then appears
in circulation bound to holo-transcobalamin-I (holo-TC-I), holo-transcobalamin-II (holo-TC-II), and
holo-transcobalamin-III (holo-TC-III). It is estimated that 20–30% of the total circulating B12 is bound
to holo-TC-II and only this form is available to the cells [7]. Holo-TC-I binds 70–80% of circulating
B12, preventing the loss of the free unneeded portion [6]. Vitamin B12 is stored mainly in the liver
and kidneys.
Many mechanisms have been proposed to explain how MET interferes with the absorption of B12:
diminished absorption due to changes in bacterial flora, interference with intestinal absorption of the
IF–B12 complex (and)/or alterations in IF levels. The most widely accepted current mechanism suggests
that MET antagonizes the calcium cation and interferes with the calcium-dependent IF–B12 complex
binding to the ileal cubilin receptor [8,9]. The recognition and treatment of B12 deficiency is important
because it is a cause of bone marrow failure, macrocytic anemia, and irreversible neuropathy [10].
In general, previous studies on diabetics have observed a reduction in serum levels of B12 after
both short- and long-term MET treatment [1]. A recent review on observational studies showed
significantly lower levels of B12 and an increased risk of borderline or frank B12 deficiency in patients on
MET than not on MET [1]. The meta-analysis of four trials (only one double-blind) found a significant
overall mean B12 reducing effect of MET after six weeks to three months of use [1]. A secondary
analysis (13 years after randomization) of the Diabetes Prevention Program Outcomes Study, which
randomized over 3000 persons at high risk for type 2 diabetes to MET or placebo, showed a 13%
increase in the risk of B12 deficiency per year of total MET use [3]. In this study, B12 levels were
measured from samples obtained in years 1 and 9. Stored serum samples from other time points,
including baseline, were not available, and potentially informative red blood cell indices that might
have demonstrated the macrocytic anemia, typical of B12 deficiency, were not recorded [3]. The HOME
(Hyperinsulinaemia: the Outcome of its Metabolic Effects) study, a large randomized controlled trial
investigating the long-term effects of MET versus placebo in patients with type 2 diabetes treated with
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insulin, showed that the addition of MET improved glycemic control, reduced insulin requirements,
prevented weight gain but lowered serum B12 over time, and raised serum homocysteine, suggesting
tissue B12 deficiency [4]. A recent analysis of 277 diabetics from the same trial showed that serum
levels of MMA, the specific biomarker for tissue B12 deficiency [5], were significantly higher in people
treated with MET than those receiving placebo after four years (on average) [4].
The risk of MET-associated B12 deficiency may be higher in older individuals and those with
poor dietary habits. Prospective studies have found negative associations between obesity and B12
in numerous ethnicities [11,12]. An energy-dense but micronutrient-insufficient diet consumed by
individuals who are overweight or obese might explain this [12]. Furthermore, obesity is associated
with low-grade inflammation and these physiological changes have been shown to be associated, in
several studies, with elevated C-reactive protein and homocysteine and with low concentrations of B12
and other vitamins [13,14].
As part of a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET for
primary prevention of breast cancer and other chronic age-related diseases in healthy women with
tracts of MS [15] we tested the effect of MET on serum levels of B12, holo-TC-II, and MMA.
2. Material and Methods
2.1. Study Design
A pilot phase III randomized controlled trial of MedDiet and MET is ongoing at the Fondazione
IRCCS Istituto Nazionale dei Tumori in Milan (Ethic approval code: INT76/08) for the primary
prevention of breast cancer and other chronic age-related diseases in healthy peri-postmenopausal
women with a waist circumference ≥85 cm and at least one other component of the metabolic syndrome
reported below
- high plasma glucose (≥100 mg/100 mL)
- high triglycerides (≥150 mg/100 mL)
- low HDL cholesterol (<50 mg/100 mL)
- systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg.
The study design is a double-blind 2 × 2 factorial with 400 volunteers randomized in four groups
of 100 each and allocated to the following treatments:
- MET (1700 mg/day) + MedDiet intervention
- Placebo + MedDiet intervention
- MET (1700 mg/day) alone
- Placebo alone.
At baseline, participants were asked to sign an informed consent form and attend an anthropometric
visit, giving blood and urine samples. The baseline measurements served to check the tracts of the
metabolic syndrome and the absence of exclusion criteria. The exclusion criteria were: diabetes,
fasting glycemia more than 126 mg/dL in two repeated blood samples or concomitant treatment with
MET, diagnosis of cancer in the last five years (except skin carcinomas), serum creatinine more than
124 micromol/L, proteinuria, concomitant treatment with potassium-sparing diuretics or proton pump
inhibitors, and excessive alcohol consumption. The study lasted five years, with a MET/placebo
treatment of three years on average. Once a year for the five years of the study each participant
repeated the anthropometric visit and blood sampling, on approximately the same date as the previous
one, as required by the study protocol.
The trial is now being extended to include 1600 women and men with MS (the Me.Me.Me. trial;
ethic approval code: INT76/08) [16].
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2.2. Participants
Among the 400 volunteers included in the trial, we selected 165 healthy women, aged 46–73 years,
to test the effect of MET on serum levels of B12, holo-TC-II, and MMA. The sampled 165 women were
selected on the basis of the following criteria: three years of MET or placebo treatment at the time of
the analysis and availability of before and after treatment blood samples. Forty-four women were
allocated to MET + MedDiet intervention, 37 to Placebo + MedDiet intervention, 37 received MET
alone, and 47 Placebo alone.
2.3. Measurements
Blood samples were drawn at baseline and at each scheduled time points and sera were frozen at
−70 ◦C and never thawed.
The B12 was determined on the baseline and after three years of samples using the
Electro-Chemiluminescence Immuno Assay (ECLIA) method (COBAS E 601 autoanalyzer, Roche
Diagnostic). The B12 measuring range was 50.0–2000 pg/mL. For internal quality control we used
PreciControl Varia (Roche Diagnostic), two levels (normal and pathological). Furthermore, for the B12
tests, our laboratory participates in external quality certification programs organized by the Lombardy
Region (Italy).
Quantitative determination of holo-TC-II (active-B12) was done using chemiluminescent
microparticle immunoassay technology (Abbott Diagnostics, Wiesbaden, Germany). The measuring
interval range of the Holo-TC-II assay (active-B12) was 5.0–128 pmol/L. Samples with values above
128 pmol/L were diluted with “architect multi-assay manual diluents” according to the manufacturer’s
instructions. The performance of the instrument was evaluated using two levels, low and high, internal
quality controls.
The MMA was determined by a liquid chromatographic separation and isotopic dilution mass
spectrometric technique (ID-MSMS). The MMA measuring range was 6.25–200 ng/mL. A pool of
plasma was used as internal quality control.
Inter-assay precision was investigated according to the Clinical and Laboratory Standards Institute
(CLSI) protocol. The coefficients of inter-assay variation were respectively: <5.2% for total B12, <8% for
holo-TC-II, and <7.9% for MMA.
2.4. Criteria and Source of Cut-Offs Used
2.4.1. Vitamin B12 Assay
According to the World Health Organization (WHO), B12 status in adults is defined by the serum
levels of the micronutrient with the following cut-off and definitions: ≥221 pmol/L is vitamin “B12
adequacy” (i.e., normal); between 148 and 221 pmol/L is “low B12”, and lower than 148 pmol/L is “B12
deficiency” (i.e., very low) [17,18]. Vitamin B12 levels <148 pmol/L have sensitivity exceeding 95% in
patients with megaloblastic anemia [19,20], and this cut-off is most commonly used in research and
clinical fields [20].
2.4.2. Holo-TC-II Assay
The diagnostic accuracy of holo-TC-II remains controversial. The test is thought to have sensitivities
and specificities comparable to that of serum B12 with regard to MMA elevations [5]. Several studies
suggest that holo-TC-II slightly outperforms the B12 test [21,22]. The specificity of the holo-TC-II test
remains unclear. According to the WHO guidelines, holo-TC-II levels are defined “normal” if higher
than 50 pmol/L, “low” from 35 to 50 pmol/L and “very low” if lower than 35 pmol/L.
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2.4.3. MMA Assay
Vitamin B12, under the catalysis of the enzyme methylmalonyl-CoA mutase, synthesizes
succinyl-CoA from methylmalonyl-CoA in the mitochondria. Deficiency of B12 thus results in
elevated MMA levels. A high MMA test result has >95% sensitivity for B12 deficiency in patients with
pernicious anemia [4]. Methylmalonic acid test cut-offs between 210 and 480 nmol/L are used to define
B12 deficiency. The cut-off of ≥271 nmol/L is currently the most commonly used [23,24].
2.5. Statistical Analysis
After checking for the completeness and consistency of the data we employed two-way ANOVA
to investigate the effect of treatment (placebo or MET) and/or that of diet (free or MedDiet) on the
pivotal variables of interest (holo-TC-II, Vitamin B12 and MMA levels) on their original continuous
scale. Specifically, in these models the response variable, i.e., the difference (∆T1–T0) between the
biomarker levels at baseline (T0) and after three years (T1), was modeled as a function of the main
effect “treatment” (placebo or MET) and “diet” (free or MedDiet) and their first-order interaction term.
The Fisher exact test was finally implemented to assess possible associations between the WHO’ deficit
conditions and the four experimental groups.
All statistical analyses were performed with SAS software (Version 9.4.; SAS Institute, Inc., Cary,
NC, USA), adopting a nominal significance level of α = 0.05.
3. Results
The subjects’ baseline anthropometric and clinical chemical parameters are shown in
Supplementary Materials Table S1, and hematologic variables at baseline and after three years, in
Supplementary Materials Table S2. There appeared to be no alterations to kidney and/or hematological
function. Descriptive statistics for B12, holo-TC- II, and MMA at baseline (T0) and after three years (T1)
are reported in Table 1.
Table 1. Descriptive statistics of the variables investigated.
Group Time n Min 25th Centile Median 75th Centile Max IQR
B12 [pmol/L]
M-MedDiet
baseline 44 143.7 276.4 335.3 402.0 756.9 125.7
3rd year 44 120.9 205.3 262.4 354.9 765.7 149.6
M-FreeDiet
baseline 37 150.3 268.3 350.1 470.9 1474.0 202.7
3rd year 37 109.8 193.1 284.5 420.8 1474.0 227.7
P-MedDiet
baseline 37 136.3 260.2 316.9 353.0 817.3 92.9
3rd year 37 147.4 244.7 299.2 381.0 844.6 136.3
P-FreeDiet
baseline 47 195.3 287.4 358.2 426.7 642.7 139.3
3rd year 47 46.4 255.7 330.9 412.7 1312.6 157.0
Holo-TC-II
[pmol/L]
M-MedDiet
baseline 44 34.0 85.5 112.5 140.0 402.0 54.5
3rd year 44 22.1 61.5 84.0 117.5 416.0 56.0
M-FreeDiet
baseline 37 47.0 91.0 109.0 152.0 780.0 61.0
3rd year 37 34.0 66.0 83.0 119.0 246.0 53.0
P-MedDiet
baseline 37 58.0 89.0 100.0 121.0 248.0 32.0
3rd year 37 48.0 85.0 108.0 126.0 192.0 41.0
P-FreeDiet
baseline 47 49.0 88.0 115.0 138.0 248.0 50.0
3rd year 47 41.0 80.0 112.0 140.0 238.0 60.0
MMA [nmol/L]
M-MedDiet
baseline 44 83.9 105.5 132.6 182.6 359.3 77.1
3rd year 44 78.0 120.8 139.4 195.7 411.8 75.0
M-FreeDiet
baseline 37 71.2 106.8 125.4 156.8 341.5 50.0
3rd year 37 89.8 119.5 144.9 170.3 422.0 50.8
P-MedDiet
baseline 37 69.5 92.4 106.8 145.8 221.2 53.4
3rd year 37 75.4 99.1 126.3 150.0 244.1 50.8
P-FreeDiet
baseline 47 83.9 105.9 131.3 163.5 258.5 57.6
3rd year 47 72.0 105.9 137.3 163.5 377.9 57.6
Abbreviations: n = number, IQR = Inter Quartile Range, Holo-TC-II = Holo-transcobalamin-II,
MMA = Methylmalonic acid.
The ANOVA results for both the total serum B12 levels and holo-TC-II absolute differences
concentrations indicated significant decreases in the main effects for the treatment factor (p = 0.02 and
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p = 0.01, respectively). The diet factor, neither alone (p = 0.58 and p = 0.09) nor with treatment (p = 0.89
and p = 0.28), significantly contributed to the reductions in biomarkers.
Serum MMA showed no significant changes either in the main effects (p = 0.17 for treatment and
p = 0.92 for diet) or in the interaction terms (p = 0.30). Figure 1 shows the interaction plots: with the
levels of the treatment factor (placebo and MET) on the x-axis and the mean values of the response
variables (a) B12, (b) holo-TC-II, and (c) MMA on the y-axis, with separate lines (continuous and dotted)
for the two levels of the diet factor (Free and MedDiet).
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On the basis of WHO guidelines, we examined the sample’s deficit conditions at the end of the
interventions (Table 2): WHO guidelines on B12 status define “adequate” B12 values as higher or equal
to 221 pmol/L (i.e., normal), “low” from 148 to 221 and “B12 deficiency” if lower than 148 (i.e., very low).
Holo-TC-II levels are defined “normal” if higher than 50 pmol/L, “low” from 35 to 50, and “very low”
if lower than 35. Methylmalonic acid levels are considered “normal” if below the cutoff of 271 nmol/L.
As regards B12, 26 of 81 MET-treated patients and 10 of 84 placebo-treated subjects had levels below
the normal threshold meaning that around 22% of the total study population did not have adequate
total B12 levels at the end of the study. Holo-TC-II levels were “low” or “very low” in 16 subjects, 11
MET-treated and five placebo-treated. Methylmalonic acid levels were above the normal threshold in
less than 7% of the MET treated patients and in one placebo-treated subject. As reported in Table 2, no
associations were observed between WHO’s deficit conditions and the four experimental groups for
both Holo-TC-II and MMA levels (Fisher exact test, p-value: 0.63, 0.40, respectively). On the contrary,
for B12, a statistically significant association was observed Fisher exact test, p-value: 0.02).
Considering jointly all the biochemical parameters (B12, holo-TC-II and MMA), 13 subjects
(10 MET- and 3-placebo-treated) out of 165 had at least two deficits in the biochemical parameters at
T1. However, patients reported no clinical signs.
Table 2. Frequency distribution of B12 deficit status at T1 according to World Health Organization
WHO guidelines, for each treatment group.
Total B12 Holo-TC-II MMA
Normal Low Very Low Normal Low Very Low Normal Pathological
n % n % n % n % n % n % n % n % n %
M-MedDiet 44 54.3 30 37.0 12 14.8 2 2.5 37 45.7 5 6.2 2 2.5 41 50.6 3 3.7
M-FreeDiet 37 45.7 25 30.9 9 11.1 3 3.7 33 40.7 3 3.7 1 1.2 35 43.2 2 2.5
total 81 100.0 55 67.9 21 25.9 5 6.2 70 86.4 8 9.9 3 3.7 76 93.8 5 6.2
P-MedDiet 37 44.0 32 38.1 4 4.8 1 1.2 35 41.7 2 2.4 0 0.0 37 44.1 0 0.0
P-FreeDiet 47 56.0 42 50.0 2 2.4 3 3.6 44 52.4 3 3.6 0 0.0 46 54.8 1 1.2
total 84 100.0 74 88.1 6 7.1 4 4.8 79 94.0 5 6.0 0 0.0 83 98.8 1 1.2
Abbreviations: M = Metformin, P = Placebo, MedDiet = Mediterranean diet, Holo-TC-II = Holo-transcobalamin-II,
MMA = Methylmalonic acid. Percentages were computed with respect to the total number of subjects treated with
metformin or placebo, respectively.
4. Discussion
In line with previous studies in diabetics, our data indicate that long-term use of MET lowers
circulating B12 levels in healthy women with tracts of MS. The decline was significant in all groups of
MET-treated subjects regardless of the MedDiet intervention. Almost a third (32%) of the women in
the trial presented B12 deficiency (<221 pmol/L) after three years of MET daily doses of 1700 mg: these
results were similar to those from other studies (8.6%–31%) [1–3].
Metformin is the most widely prescribed oral medication for type-2 diabetes. Given its potential
anti-cancer effect [25–31], several trials are ongoing in non-diabetics now too [15,16,32]. Our results are
a novelty because they are the first ones including women free of acute and/or chronic diseases. The
aim of the present study was to check safety, evaluating the effect of MET in term of its effects over time
on serum levels of B12, holo-TC-II, and MMA in women under treatment for three years. For the same
purpose, we also checked the participants’ blood counts for any sign of macrocytic anemia, as well as
their hemoglobin and hematocrit. We considered it essential to confirm that long-term treatment with
1700 mg/day of MET, a potential “preventive” drug, is completely safe.
Despite the reduction in B12 levels, our results do not suggest the on-set of clinical B12 deficiency nor
any clinical effect that might influence whether women remain in the trial. A recent meta-analysis about
B12 deficiency (comprising 31 studies) showed that, compared to diabetics not taking MET, patients
taking the drug had a significantly higher risk of B12 deficiency and lower serum B12 concentration, in
a duration- and dose-dependent manner, without any significant association between MET use and
prevalence of anemia [33]. Furthermore, subgroup analyses indicated that only patients with a mean of
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more than three years of MET therapy or patients on mean daily doses of >2000 mg had a significantly
higher risk of B12 deficiency than patients not taking MET. In this larger meta-analysis, the deficiency
was diagnosed using only the direct measurement of circulating B12 which, however, is not considered
to sufficiently reflect its metabolic status [34].
The strength of our study is the “global” evaluation of the B12 status of participants, also taking
into account serum levels of holo-TC-II and MMA. Holo-TC-II was below the cut-off (≤50 pmol/L)
in 11 women (14%) after the third year of MET treatment. The MMA levels were above the normal
threshold in less than 7% of the MET-treated patients and one placebo-treated subject.
Herrmann et al. [35] reported that MMA assay leads to a three-block classification of patients, where:
(1) MMA < 271 with holo-TC-II < 35 represents a negative B12 balance (insufficiency); (2) MMA < 271
with holo-TC-II 36–50 suggests the patient is unlikely to be B12-deficient; and (3) a range of possible
B12-deficient patients have MMA ≥ 271 and low or very low holo-TC-II. According to this classification,
it is evident that only holo-TC-II gives important information about B12 status because MMA rises only
after the declines in B12 and holo-TC-II become important (very low). In our series, five MET-treated
subjects had high MMA ≥ 271 but only one had low B12 and holo-TC-II. Furthermore, in the placebo
group, just one subject had an increase only in MMA.
Considering all the biochemical parameters together (B12, holo-TC-II, and MMA), only 13 subjects
(10 MET- and 3-placebo-treated) out of 165 had at least two deficiencies in T1. However, no clinical
signs were found in hematologic data or reported by patients. This small number might be attributable
to the large amount of B12 in the human body—approximately 2000–4000 µg (stored primarily in the
liver). Roughly 1 µg of B12 is consumed every day; thus, many years (at least ten) are necessary to
reach a deficit status, which helps explain why we detected so few cases of biochemical deficiency after
three years. It is reasonable to believe that even longer is needed to detect a clinical B12 deficiency.
Furthermore, the cause of MET-induced B12 deficiency is not known, but it appears to involve altered
uptake of the cubilin receptor, which reduces B12 absorption in the ileum.
Another mechanism has been hypothesized for the low serum B12 levels during MET use. Several
groups have noted that in rodent models, MET treatment increases the accumulation of B12 in the
liver, lowering circulating vitamin B12 levels, suggesting that MET alters the tissue distribution and
metabolism of B12, rather than causing true deficiency. This novel mechanism might also explain the
absence of clinical signs despite the apparently very low levels of B12; thus, the definition of vitamin
deficiency, based only on serum levels, might be incorrect. Holo-TC-II assay might give more valuable
information, although true vitamin deficiency can be definitively diagnosed only on the basis of an
increase in MMA and the presence of clinical conditions (megaloblastic anemia, neuropathies).
Finally, some notes about the possible limitations of the current study should be mentioned. The
current study considered all the women treated with MET or placebo for three years at the time of the
analysis and with both baseline and 3-year blood samples available. Further evaluations considering
also additional time points could provide additional information about MET long-term treatment on
B12 reduction.
Another limit is that we were not able to study dietary components. Our results did not suggest
any contribution of the MedDiet intervention to the B12 reduction, either alone or in combination with
MET. Unfortunately, we did not use repeated dietary assessment methods to check compliance with
the diet. In fact, according to the trial design, the main method for assessing dietary differences in
the MedDiet and FreeDiet group was based on anthropometry and clinical chemistry, and 24 h food
frequency diaries concerning food eaten the previous day were scheduled at baseline and at the end of
the five-year intervention.
Current guidelines do recognize the risk of B12 deficiency as a disadvantage of MET treatment
for type 2 diabetes [21]. However, this is rarely investigated in diabetics. We found that after three
years of treatment the frequency of MET-induced B12 biochemical deficiency was low and the cases
detected had no clinical-hematological signs. Given these results, three years of MET treatment (as
provided by our trial protocol) do not seem to be associated with clinical deficiency of B12. However,
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given the growing population of individuals who receive MET for other indications (including high
risk of diabetes, polycystic ovary syndrome, metabolic syndrome, cancer prevention), and the chronic
nature of these treatments, we feel that monitoring of B12 (and Holo-TC-II, if B12 levels are low-normal)
in MET-treated individuals should be considered routinely before starting and during treatment.
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